Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 700 of 3499 entries
View as:

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02101853 Org: User:
Start: 12/17/14 End: 09/18/25 Due: 09/18/26

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02112916 Org: User:
Start: 10/04/14 End: 09/18/25 Due: 09/18/26

Cilengitide in Treating Patients With Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00121238 Org: User:
Start: 01/31/05 End: 11/30/15 Due: 11/30/16

A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT00001430 Org: User:
Start: 02/28/95 End: 01/31/02 Due: 01/31/03

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

Phase: N/A Priority: Normal
NCT ID: NCT04535401 Org: User:
Start: 08/13/21 End: 04/29/25 Due: 04/29/26

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Phase: N/A Priority: Normal
NCT ID: NCT03526250 Org: User:
Start: 08/13/18 End: 09/30/24 Due: 09/30/25

Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma

Phase: N/A Priority: Normal
NCT ID: NCT01208454 Org: User:
Start: 12/31/10 End: - Due: -

Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00049088 Org: User:
Start: 08/31/02 End: - Due: -

Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy

Phase: N/A Priority: Normal
NCT ID: NCT00072137 Org: User:
Start: 10/31/03 End: 11/30/10 Due: 11/30/11

Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00324870 Org: User:
Start: 02/28/06 End: 11/30/13 Due: 11/30/14

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

Phase: N/A Priority: Normal
NCT ID: NCT04439149 Org: User:
Start: 02/25/16 End: 11/30/25 Due: 11/30/26

Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption

Phase: N/A Priority: Normal
NCT ID: NCT05419024 Org: User:
Start: 01/09/23 End: 08/01/26 Due: 08/01/27

Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT01012297 Org: User:
Start: 11/30/09 End: 09/30/15 Due: 09/30/16

Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00002574 Org: User:
Start: 09/30/94 End: - Due: -

BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00006213 Org: User:
Start: 04/30/00 End: - Due: -

Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00303966 Org: User:
Start: 11/30/05 End: 05/31/11 Due: 05/31/12

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

Phase: N/A Priority: Normal
NCT ID: NCT05687110 Org: User:
Start: 07/06/23 End: 09/01/26 Due: 09/01/27

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01381692 Org: User:
Start: 07/20/11 End: 09/01/21 Due: 09/01/22

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01328574 Org: User:
Start: 03/31/11 End: 11/30/14 Due: 11/30/15

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Phase: N/A Priority: Normal
NCT ID: NCT05372614 Org: User:
Start: 10/05/22 End: 12/01/25 Due: 12/01/26

Dinaciclib in Treating Patients With Stage IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00937937 Org: User:
Start: 07/01/09 End: 03/19/26 Due: 03/19/27

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01013649 Org: User:
Start: 04/05/10 End: 02/13/26 Due: 02/13/27

Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03803774 Org: User:
Start: 09/25/19 End: 03/20/26 Due: 03/20/27

Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00238394 Org: User:
Start: 12/31/05 End: - Due: -

Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02379416 Org: User:
Start: 04/13/15 End: 06/27/26 Due: 06/27/27